Efficacy and safety of enzalutamide (ENZA) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities (CMDs) and/or related concomitant medications (meds): ARCHES post hoc.
A Stenzl, Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore et autres
0 citationsJournal of Clinical Oncology